Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

  • Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 6/3/19 (What's New)

References

AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-hivhcv-coinfection. Accessed May 31, 2019.[AASLD/IDSA HCV]

Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(suppl 1):27-37.[Abel 2008]

Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13:683-689.[Alvarez 2006]

Amorosa VK, Slim J, Mounzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther. 2010;15:91-99....

Action required

Keywords: Drug-Drug Interactions, Pharmacokinetics

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.